Andrea Bruell

Andi Bruell joined Biogen Idec in 2010 as VP, US Marketing. Under her leadership, the Marketing team established a new vision, transformed the culture, and delivered record breaking sales performance. In January 2013, Andi assumed a new role in Global Commercial Strategy as VP, New Product Commercialization responsible for the commercial leadership of early stage pipeline, the collaboration with Genentech/Roche on Rituxan, and all Business Development and M&A activities. In this role Andi is focused on building a long term future for Biogen Idec that will sustain the growth and momentum achieved with the launch of Tecfidera. Prior to joining Biogen Idec, Andi spent more than ten years at Johnson & Johnson where she was most recently Executive Director, Global Marketing Leader, Immunology. In this role Andi led global teams responsible for the commercialization, launch readiness and life-cycle planning for J&J’s major new and emerging therapies like SIMPONI and CNTO 136. Earlier in her tenure with J&J, Andi led the global marketing for blockbuster drugs like TOPAMAX. Her career includes earlier roles in strategic product development for GlaxoSmithKline where she launched AVANDIA, and brand management positions to support hemophilia products. Andi brings many years of biotech and specialty pharmaceutical marketing leadership experience across numerous therapeutic areas including rheumatology, endocrinology, neurology, hematology and dermatology. Her track record includes successful launches of five specialty therapies, lifecycle management of existing therapies and the ability to provide a strong strategic vision for her teams. She understands the unique challenges in the specialty market space and knows what it takes to be successful.

Innovation, leadership, and mentoring women